Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition

Core Insights - Hims & Hers Health (HIMS) shares surged approximately 20% to a new record high following the acquisition of Trybe Labs [1][4] Group 1: Acquisition Details - The acquisition of Trybe Labs enables Hims & Hers to introduce at-home blood testing services, providing customers with insights into various health metrics such as hormone levels, cardiac risk, and cholesterol [2][4] - The company has completed the acquisition but did not disclose the financial terms, funding the deal with cash on hand [3] Group 2: Financial Position - At the end of the third quarter, Hims & Hers reported approximately $166 million in cash or cash equivalents and over$600 million in total assets [3] - The announcement of the acquisition precedes the company's fourth-quarter earnings report, which is scheduled for release after market close on Monday [3]